Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Theoretical Biology and Medical Modelling

Figure 6

From: A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent

Figure 6

Comparisons of proliferating cell counts in the absence and presence of HIA and CTA treatment. Solution trajectories for P are plotted against one another in various cases in order to determine the effect that HIA and CTA have on the number of proliferating stem cells. A. Trace 1 shows the solution trajectory for the heightened steady state in the presence of CTA and absence of HIA. Trace 2 shows the solution trajectory in the presence of both CTA and HIA. It can be seen that CTA treatment alone causes a decrease in the equilibrium value of P compared to when CTA treatment is absent. The addition of HIA with CTA prevents the solution trajectory from reaching the extreme minimum that is reached when CTA treatment is administered alone. B. Solution trajectories for high (trace 1, β0,C = 0.301), medium (trace 2, β0,C = 0.206), and low (trace 3, β0,C = 0.048) doses of CTA treatment in the absence of HIA are plotted. As the dosage increases, the steady state value of the proliferating cells decreases. C. Simulations of P are shown with CTA treatment alone (trace 1) and at low (trace 2), moderate (trace 3) and high (trace 4) dosages of HIA administration in conjunction with CTA treatment. At a moderate dosage, the minimum value of P is close to the steady state value of the control case.

Back to article page